BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal

Biogen's (BIIB) New Drug Application for Nusinersen, an investigational treatment for spinal muscular atrophy, has been accepted for priority review by the FDA.

from RTT - Biotech http://ift.tt/2eKI0ca
via IFTTT